Ninety-two patients were entered in a double-blind controlled trial of long-acting quinidine bisulphate for the maintenance of sinus rhythm following DC reversion of atrial fibrillation. By random selection two statistically comparable groups of patients were obtained, a control group being given a placebo and a treated group quinidine bisulphate I -5 g. per day in two Z2-hourly doses. Thirty-seven patients were followed up in the control group and twenty-eight patients in the treated group. The maintenance of sinus rhythm in the treated group was significantly longer than in the control group, especially during the first three months. The mean serum quinidine level in the treated group was 2-2 ± o03 (SEM) mg. per litre. There was one death among the patients treated with quinidine, which may have been due to quinidine toxicity caused by a high serum quinidine level.
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From the Cardiac Department, St. Thomas' Hospital, London S.E. i Ninety-two patients were entered in a double-blind controlled trial of long-acting quinidine bisulphate for the maintenance of sinus rhythm following DC reversion of atrial fibrillation. By random selection two statistically comparable groups of patients were obtained, a control group being given a placebo and a treated group quinidine bisulphate I -5 g. per day in two Z2-hourly doses. Thirty-seven patients were followed up in the control group and twenty-eight patients in the treated group. The maintenance of sinus rhythm in the treated group was significantly longer than in the control group, especially during the first three months. The mean serum quinidine level in the treated group was 2-2 ± o03 (SEM) mg. per litre. There was one death among the patients treated with quinidine, which may have been due to quinidine toxicity caused by a high serum quinidine level.
Sinus rhythm is more efficient haemodynamically and as a rate regulator than atrial fibrillation. In addition, patients reverted to sinus rhythm are relieved of palpitations and are less liable to suffer embolic episodes (Lown, I967) . Reversion of atrial fibrillation to sinus rhythm became simple and safe when DC countershock superseded drug reversion (Lown, Amarasingham, and Neuman, I962) . The main problem now is the maintenance of sinus rhythm after the procedure.
There is controversy about the value and potential danger of using quinidine for maintenance therapy. Some authors state that it should be used prophylactically before DC reversion of arrhythmias and afterwards to maintain sinus rhythm (Lown et Morris, Peter, and McIntosh, I966; Rossi and Lown, I967; Lown, i967) , while others have considered that it does not prolong the duration of sinus rhythm (Chevalier, I966; Halmos, I966; Szekely, Batson, and Stark, I966; Hall and Wood, 1968) . The dangers of quini-In this paper we report the results of a double-blind controlled trial of a long-acting preparation of quinidine bisulphate (Kinidin Durules) for the maintenance of sinus rhythm after DC reversion of atrial fibrillation. This preparation produces a slow and prolonged release of quinidine bisulphate. The high peak in blood concentration that occurs after quinidine sulphate is replaced by a plateau which develops gradually and is maintained over 12 hours (Cramnr, Varnauskas, and Werko, I963; Siitonen, I964).
Patients and Methods
Ninety-two patients who had atrial fibrillation and were admitted to hospital between March 1966
and September I967 for DC reversion were included in the trial. They were randomly allocated to two groups-A and B. An identical tablet was provided for each group. Group A tablet contained placebo, and Group B 0-25 g. quinidine bisulphate in a sustained-release formn (Kinidin Durules) .
This amount of quinidine bisulphate is equivalent to 0-2 g. quinidine sulphate. Henceforth these two groups will be called Group A (control) and Group B (quinidine). The patients were told the nature of the trial but neither they nor the authors knew which tablet contained quinidine bisulphate.
Patients were admitted to hospital for two nights. Digoxin was stopped at least 24 hours before admission. A test dose of quinidine sul- The distribution between groups is not significantly different. Ischaemic and/or hypertensive 6 (I2-8%) 9 (20-0%) i5 (I6-3%) Thyrotoxic 2 (4-3%)
The distribution between the groups and between the totals of rheumatic and nonrheumatic heart disease is not significantly different.
and Group B (quinidine) according to age, sex, duration of atrial fibrillation (Table I) , and aetiology ( In Table 3 it is shown that 37 patients in Group A (control) and 28 in Group B (quini- (42 9%). Thus 9 patients (24 3%) remained in sinus rhythm in Group A (control) and i6 (57'I%) in Group B (quinidine).
The results as expressed in Table 3 do not indicate the duration of sinus rhythm in each group. This is achieved by computing the result by the life-table, or actuarial method given in Table 4 . From this it can be seen that the majority of relapses to atrial fibrillation occurred during the first three months: 24 (65%) in Group A (control) and 9 (32%) in Group B (quinidine). The cumulative proportion of those patients who remained in sinus rhythm from the time of DC reversion to the end of a given interval is given in column 8. The Fig. is obtained by converting the figures in column 8 to percentages and plotting these against time. This shows graphically the considerable difference in the maintenance of sinus rhythm between the two groups in favour of Group B (quinidine).
Rheumatic and non-rheumatic heart disease. The distribution of patients with rheumatic and non-rheumatic heart disease between the groups was not significantly different in the total number of 92 entered (Table 2 ). Table 5 shows that this remained so in the 65 patients followed up. In addition, this (con-(quini-(con-(quini-(con-(quini-(con-(quini-(con-(quini-(con-(quini-(con-(quinitrol) These figures show no significant difference between rheumatic and non-rheumatic heart disease at the IO% level.
vert in Group A (control) was 146 ± I2 6 (SEM) joules and in Group B (quinidine) I28 ± I2z5 joules. These differences are not statistically significant. Serum quiiidine The results of serum quinidine estimations in Group B (quinidine) are given in Table 6 . The mean for all estimations was 2*2±0-I (SEM) mg./litre. There was no significant difference between the serum quinidine levels at the time of reversion and at the time of follow-up, nor between the levels of those patients who relapsed to atrial fibrillation or who remained in sinus rhythm. Discussion By conducting a double-blind controlled trial and by random selection, obtaining two statistically comparable groups, it has been shown group.bmj.com on April 5, 2017 -Published by http://heart.bmj.com/ Downloaded from conclusively that maintenance therapy with a long-acting quinidine bisulphate preparation (Kinidin Durules) prolongs the duration of sinus rhythm after DC reversion of atrial fibrillation.
Various authors have reported that over one-third of cases who relapsed to atrial fibrillation after successful DC reversion to sinus rhythm did so within the first three months (Korsgren et (Fig) . In addition to their trial they showed that patients with non-rheumatic heart disease maintained sinus rhythm significantly longer than those in the rheumatic group. We have found no significant difference in the number relapsing during the critical first three months with either aetiology. It is difficult to explain why the control group in the present trial did so badly as compared with theirs. It appears that their patients with rheumatic heart disease fared better without quinidine.
Advocates of quinidine therapy have suggested that relapse to atrial fibrillation after successful reversion to sinus rhythm will Ball (1956) found that myocardial toxicity was infrequent at serum quinidine levels of 6-o mg./litre by their method (Edgar and Sokolow, 1950 ). This level is equivalent to 3.5 mg./litre by the method used in this study, and it has been our policy since the trial not to exceed this level.
